查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2108240

人類免疫缺乏病毒第一型市場分析及至2035年預測：類型、產品、服務、技術、應用、最終用戶、解決方案、給藥途徑、疾病階段

Human Immunodeficiency Virus Type-1 Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Solutions, Mode, Stage
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球人類免疫缺乏病毒第一型（HIV-1）市場預計將從2025年的392億美元成長到2035年的705億美元，複合年成長率（CAGR）為6.0%。 HIV - 1市場持續擴張的原因在於全球診斷覆蓋率的提高以及對治療監測需求的成長。根據聯合國愛滋病規劃署（UNAIDS）的數據，全球約有3,990萬人感染HIV，當年報告的新增感染病例約130萬例。世界衛生組織（WHO）也支持利用快速診斷方法和核酸分析技術擴大HIV檢測範圍，以提高早期發現率。產業預測表明，在政府資助的篩檢項目、技術創新以及對檢測設施基礎設施的廣泛投資的推動下，未來幾年全球HIV診斷市場預計將以中高個位數複合年成長率成長。

技術發展趨勢包括聚合酶鍊式反應（PCR）檢測、酵素連結免疫吸附試驗（ELISA）、蛋白質印跡法（Western blotting）、快速診斷檢測和新一代定序（NGS），每種技術在HIV-1的診斷和監測中都發揮著不同的作用。 PCR仍是定量病毒量和早期檢測感染的標準方法，而ELISA由於其高處理能力而被廣泛用於抗體篩檢。蛋白質印跡法雖然在常規應用中較少，但在特定情況下仍被用作確診試驗。快速檢測有助於透過分散式和照護現場篩檢來提高檢測的可及性。 NGS擴大應用於抗藥性分析、分子監測和精準醫療。持續的技術進步正在提高診斷準確性、工作流程效率和檢查室自動化程度。

市場區隔
類型 抗逆轉錄病毒療法（ART）、暴露前預防（PrEP）、暴露後預防（PEP）等。
產品 核苷類逆轉錄酶抑制劑（NRTIs）、非核苷類逆轉錄酶抑制劑（NNRTIs）、蛋白酶抑制劑（PIs）、整合酶抑制劑、進入抑制劑、固定劑量組合藥物等。
服務 診斷測試、諮詢、病患監測、藥物依從性支援及其他服務。
科技 聚合酵素鏈鎖反應（PCR）、次世代定序（NGS）、免疫檢測、就地檢驗等。
目的 臨床治療、研究與發展、公共衛生計畫及其他
最終用戶 醫院、診所、研究機構、診斷實驗室、社區醫療中心及其他
解決方案 治療方案、預防方案、診斷方案及其他
給藥途徑 口服、注射、經皮及其他劑型。
疾病階段 急性 HIV、慢性 HIV、愛滋病等

應用領域包括臨床診斷、研發和血液篩檢。臨床診斷應用最為廣泛，包括醫院和診斷實驗室的常規HIV-1篩檢、確診檢測、治療監測和病毒量評估。在研發領域，先進的分子技術正被用來闡明病毒進化、治療標靶、候選疫苗和抗藥性機制。在血液篩檢，高靈敏度的核酸擴增方法被用於檢測捐血中的HIV-1，從而確保輸血安全。隨著人們對早期診斷、醫療保健和生物醫學創新的日益重視，公共衛生系統和私人檢測實驗室的應用機會也不斷擴大。

區域概覽

北美憑藉其先進的醫療基礎設施、廣泛的分子診斷能力和完善的保險報銷體系，在人類免疫缺乏病毒第一型（HIV-1）市場中保持主導地位。該地區受益於醫院和參考實驗室對基於PCR的診斷、新一代定序和自動化檢測平台的廣泛應用。強力的公共衛生政策、持續的HIV預防和監測資金投入以及生物技術公司的積極參與正在推動市場擴張。積極的臨床研究、有利的監管流程以及抗逆轉錄病毒療法的廣泛應用，進一步增強了對創新HIV-1診斷技術和監測解決方案的持續需求。

在亞太地區，醫療保健投資的增加、診斷服務的改善以及人們對愛滋病預防計畫的日益關注，正推動著市場的顯著擴張。多個國家的政府正致力於加強疾病監測、擴大血液篩檢基礎設施，並透過國家醫療保健舉措促進早期診斷。檢查室現代化的進步、快速檢測技術的普及以及對分子診斷平台的投資，都為進一步的市場滲透提供了支持。不斷擴大的藥物研發、國際和本地醫療機構之間的合作以及醫療保健服務的改善，為先進的HIV-1檢測和監測技術的長期應用創造了有利條件。

主要趨勢和促進因素

分子診斷和就地檢驗正在改變 HIV-1 的檢測方式。

為了提高HIV-1的早期檢測和治療監測，市場正日益廣泛地採用分子診斷和分散式檢查解決方案。自動化PCR平台、用於抗藥性分析的新一代定序技術、多重診斷檢測以及數位化實驗室資訊系統的整合，正在提升臨床效率。同時，攜帶式快速診斷檢測正在資源匱乏的環境中擴大檢測範圍，從而支持旨在早期診斷和減少疾病傳播的公共衛生目標。

全球愛滋病毒篩檢和早期診斷工作正在推動市場成長。

全球為根除愛滋病毒、普及檢測和早期治療而不斷加大力度，推動了對先進HIV-1診斷技術的持續需求。政府資助的篩檢計畫、國際捐助者的支持、抗逆轉錄病毒療法的普及以及更廣泛的常規病毒載量監測，都促使醫療機構採用高靈敏度和高精度的檢測平台。技術的不斷進步也進一步提升了臨床檢查室的整體診斷能力和運作效率。

目錄

第1章摘要整理

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 抗逆轉錄病毒療法（ART）
    • 暴露前預防（PrEP）
    • 暴露後預防（PEP）
    • 其他
  • 市場規模及預測：依產品分類
    • 核苷類逆轉錄酶抑制劑（NRTIs）
    • 非核苷類逆轉錄酶抑制劑（NNRTIs）
    • 蛋白酶抑制劑（PIs）
    • 整合酶抑制劑
    • 入侵抑制劑
    • 固定劑量組合藥物
    • 其他
  • 市場規模及預測：依服務分類
    • 診斷測試
    • 諮詢
    • 病患監測
    • 藥物依從性支持
    • 其他
  • 市場規模及預測：依技術分類
    • 聚合酵素鏈鎖反應（PCR）
    • 下一代定序（NGS）
    • 免疫檢測
    • 就地檢驗
    • 其他
  • 市場規模及預測：依應用領域分類
    • 臨床治療
    • 研究與開發
    • 公共衛生計劃
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診所
    • 研究機構
    • 診斷實驗室
    • 社區健康中心
    • 其他
  • 市場規模及預測：依給藥途徑分類
    • 口服
    • 注射藥物
    • 經皮吸收
    • 其他
  • 市場規模及預測：依疾病階段分類
    • 急性HIV
    • 慢性愛滋病
    • 愛滋病
    • 其他
  • 市場規模及預測：按解決方案分類
    • 治療方案
    • 預防性解決方案
    • 診斷解決方案
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 定價和成本利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 大公司的策略

第8章：公司簡介

  • Gilead Sciences
  • ViiV Healthcare
  • Janssen Pharmaceuticals
  • Merck & Co
  • Roche
  • AbbVie
  • Bristol Myers Squibb
  • GlaxoSmithKline
  • Pfizer
  • Cipla
  • Mylan
  • Teva Pharmaceutical Industries
  • Sun Pharmaceutical Industries
  • Aurobindo Pharma
  • Dr Reddy's Laboratories
  • Hetero Drugs
  • Lupin Limited
  • Amgen
  • Vertex Pharmaceuticals
  • Boehringer Ingelheim

第9章 關於我們

簡介目錄
Product Code: GIS26140

The global Human Immunodeficiency Virus Type-1 market is projected to grow from $39.2 billion in 2025 to $70.5 billion by 2035, at a compound annual growth rate (CAGR) of 6.0%. The Human Immunodeficiency Virus Type-1 market continues to expand alongside increasing global diagnostic coverage and treatment monitoring requirements. According to UNAIDS, approximately 39.9 million people were living with HIV worldwide in 2023, with around 1.3 million new infections reported during the year. The World Health Organization also supports expanded HIV testing through rapid diagnostics and nucleic acid technologies to improve early detection. Industry assessments indicate the global HIV diagnostics market is projected to grow at a mid-to-high single-digit CAGR over the coming years, supported by government-funded screening programs, technological innovation, and broader laboratory infrastructure investments.

The technology landscape includes PCR testing, ELISA, Western blot, rapid diagnostic tests, and next-generation sequencing (NGS), each serving distinct roles across HIV-1 diagnosis and monitoring. PCR remains the benchmark for viral load quantification and early infection detection, while ELISA is widely adopted for initial antibody screening due to high throughput. Western blot continues to support confirmatory testing in selected settings despite declining routine use. Rapid tests enhance accessibility through decentralized and point-of-care screening. NGS is increasingly utilized for resistance profiling, molecular surveillance, and precision medicine applications. Continuous technological improvements are strengthening diagnostic accuracy, workflow efficiency, and laboratory automation.

Market Segmentation
TypeAntiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), Others
ProductNucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Integrase Inhibitors, Entry Inhibitors, Fixed-Dose Combinations, Others
ServicesDiagnostic Testing, Counseling, Patient Monitoring, Adherence Support, Others
TechnologyPolymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Immunoassays, Point-of-Care Testing, Others
ApplicationClinical Treatment, Research and Development, Public Health Programs, Others
End UserHospitals, Clinics, Research Institutes, Diagnostic Laboratories, Community Health Centers, Others
SolutionsTreatment Solutions, Prevention Solutions, Diagnostic Solutions, Others
ModeOral, Injectable, Transdermal, Others
StageAcute HIV, Chronic HIV, AIDS, Others

The application segment encompasses clinical diagnostics, research and development, and blood screening. Clinical diagnostics account for the largest utilization due to routine HIV-1 screening, confirmatory testing, treatment monitoring, and viral load assessments in hospitals and diagnostic laboratories. Research and development leverage advanced molecular technologies to investigate viral evolution, therapeutic targets, vaccine candidates, and drug resistance mechanisms. Blood screening ensures transfusion safety by detecting HIV-1 in donated blood using sensitive nucleic acid amplification methods. Growing emphasis on early diagnosis, preventive healthcare, and biomedical innovation continues to expand application opportunities across public health systems and commercial laboratories.

Geographical Overview

North America maintains a leading position in the Human Immunodeficiency Virus Type-1 market due to its advanced healthcare infrastructure, extensive molecular diagnostic capabilities, and well-established reimbursement systems. The region benefits from high adoption of PCR-based diagnostics, next-generation sequencing, and automated laboratory platforms across hospitals and reference laboratories. Strong public health initiatives, continuous funding for HIV prevention and surveillance, and active participation of biotechnology companies strengthen market expansion. Robust clinical research activities, favorable regulatory pathways, and widespread access to antiretroviral therapy further reinforce sustained demand for innovative HIV-1 diagnostic technologies and monitoring solutions.

Asia-Pacific demonstrates substantial market expansion driven by increasing healthcare investments, improving diagnostic accessibility, and rising awareness of HIV prevention programs. Governments across several countries are strengthening disease surveillance, expanding blood screening infrastructure, and promoting early diagnosis through national healthcare initiatives. Growing laboratory modernization, increasing adoption of rapid testing technologies, and investments in molecular diagnostic platforms are supporting broader market penetration. Expanding pharmaceutical research, collaborations between international healthcare organizations and regional institutions, and improving healthcare access create favorable conditions for long-term adoption of advanced HIV-1 testing and surveillance technologies.

Key Trends and Drivers

Molecular Diagnostics and Point-of-Care Testing Reshape HIV-1 Detection:

The market is witnessing increasing adoption of molecular diagnostics and decentralized testing solutions that improve early HIV-1 detection and treatment monitoring. Integration of automated PCR platforms, next-generation sequencing for drug resistance analysis, multiplex diagnostic assays, and digital laboratory information systems is enhancing clinical efficiency. Simultaneously, portable rapid diagnostic tests are expanding access in resource-limited settings, supporting public health objectives aimed at earlier diagnosis and reduced disease transmission.

Global HIV Screening Initiatives and Early Diagnosis Fuel Market Growth:

Growing global initiatives focused on HIV elimination, universal testing, and early treatment are driving sustained demand for advanced HIV-1 diagnostic technologies. Government-funded screening programs, international donor support, expanded access to antiretroviral therapy, and increasing implementation of routine viral load monitoring are encouraging healthcare providers to adopt highly sensitive and accurate testing platforms. Continuous technological advancements further strengthen diagnostic performance and operational efficiency across clinical laboratories.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Mode
  • 2.8 Key Market Highlights by Stage
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Antiretroviral Therapy (ART)
    • 4.1.2 Pre-Exposure Prophylaxis (PrEP)
    • 4.1.3 Post-Exposure Prophylaxis (PEP)
    • 4.1.4 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • 4.2.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • 4.2.3 Protease Inhibitors (PIs)
    • 4.2.4 Integrase Inhibitors
    • 4.2.5 Entry Inhibitors
    • 4.2.6 Fixed-Dose Combinations
    • 4.2.7 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Diagnostic Testing
    • 4.3.2 Counseling
    • 4.3.3 Patient Monitoring
    • 4.3.4 Adherence Support
    • 4.3.5 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Polymerase Chain Reaction (PCR)
    • 4.4.2 Next-Generation Sequencing (NGS)
    • 4.4.3 Immunoassays
    • 4.4.4 Point-of-Care Testing
    • 4.4.5 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Clinical Treatment
    • 4.5.2 Research and Development
    • 4.5.3 Public Health Programs
    • 4.5.4 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Clinics
    • 4.6.3 Research Institutes
    • 4.6.4 Diagnostic Laboratories
    • 4.6.5 Community Health Centers
    • 4.6.6 Others
  • 4.7 Market Size & Forecast by Mode (2020-2035)
    • 4.7.1 Oral
    • 4.7.2 Injectable
    • 4.7.3 Transdermal
    • 4.7.4 Others
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Acute HIV
    • 4.8.2 Chronic HIV
    • 4.8.3 AIDS
    • 4.8.4 Others
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Treatment Solutions
    • 4.9.2 Prevention Solutions
    • 4.9.3 Diagnostic Solutions
    • 4.9.4 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Mode
      • 5.2.1.8 Stage
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Mode
      • 5.2.2.8 Stage
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Mode
      • 5.2.3.8 Stage
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Mode
      • 5.3.1.8 Stage
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Mode
      • 5.3.2.8 Stage
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Mode
      • 5.3.3.8 Stage
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Mode
      • 5.4.1.8 Stage
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Mode
      • 5.4.2.8 Stage
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Mode
      • 5.4.3.8 Stage
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Mode
      • 5.4.4.8 Stage
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Mode
      • 5.4.5.8 Stage
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Mode
      • 5.4.6.8 Stage
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Mode
      • 5.4.7.8 Stage
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Mode
      • 5.5.1.8 Stage
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Mode
      • 5.5.2.8 Stage
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Mode
      • 5.5.3.8 Stage
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Mode
      • 5.5.4.8 Stage
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Mode
      • 5.5.5.8 Stage
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Mode
      • 5.5.6.8 Stage
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Mode
      • 5.6.1.8 Stage
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Mode
      • 5.6.2.8 Stage
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Mode
      • 5.6.3.8 Stage
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Mode
      • 5.6.4.8 Stage
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Mode
      • 5.6.5.8 Stage
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Gilead Sciences
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 ViiV Healthcare
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Janssen Pharmaceuticals
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Merck & Co
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Roche
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 AbbVie
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Bristol Myers Squibb
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 GlaxoSmithKline
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Pfizer
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Cipla
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Mylan
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Teva Pharmaceutical Industries
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Sun Pharmaceutical Industries
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Aurobindo Pharma
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Dr Reddy's Laboratories
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Hetero Drugs
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Lupin Limited
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Amgen
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Vertex Pharmaceuticals
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Boehringer Ingelheim
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us